Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
STAMFORD, Conn., May 02, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the first quarter ended March 31, 2017 on May 9, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
